These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36536701)

  • 1. Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study.
    Manda A; Koya P; Pallem R; Mohd D; Thatikonda K; Venkateshwarlu K
    Ann Med Surg (Lond); 2022 Dec; 84():104948. PubMed ID: 36536701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India.
    Deb T; Garg R; Kaur M; Beniwal A; Gupta V
    Curr Drug Saf; 2022; 17(4):344-349. PubMed ID: 35049437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects after first and second dose of covishield and covaxin: A longitudinal study.
    Mittal A; Jain B; Varshney AM; Garg G; Sachan D; Singh RB
    J Family Med Prim Care; 2022 Nov; 11(11):7339-7345. PubMed ID: 36993127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia.
    Alfaleh A; Alkattan A; Radwan N; Elzohri M; Alzaher A; Ibrahim M; Alsalameen E; Alsultan A; Alhabib D; Alshelwah A; Mahmoud N; Sagor K; Alabdulkareem K
    Drugs Ther Perspect; 2022; 38(2):84-92. PubMed ID: 35095267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reaction profile of oseltamivir in Indian population: A prospective observational study.
    Anovadiya AP; Barvaliya MJ; Shah RA; Ghori VM; Sanmukhani JJ; Patel TK; Tripathi CB
    Indian J Pharmacol; 2011 May; 43(3):258-61. PubMed ID: 21713087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study.
    El-Shitany NA; Bagher AM; Binmahfouz LS; Eid BG; Almukadi H; Badr-Eldin SM; El-Hamamsy M; Mohammedsaleh ZM; Saleh FM; Almuhayawi MS; Alghamdi SA; Arab RA; Ali SS; Harakeh S; Alghamdi BS
    Int J Gen Med; 2022; 15():6821-6836. PubMed ID: 36051568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.
    Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
    Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
    BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Radio-contrast Media-Induced Self-Reported Adverse Drug Reactions in a Tertiary Care Hospital of North India: A Prospective Study.
    Singh P; Gill MK; Kaur M; Mahajan R; Kaur M
    Int J Appl Basic Med Res; 2022; 12(1):14-17. PubMed ID: 35265475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from a Web-Based Study from India.
    Sil A; Jakhar D; Das A; Jagadeesan S; Aradhya SS
    Indian J Dermatol; 2022; 67(2):115-120. PubMed ID: 36092222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
    Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
    J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.
    Jose D; Dhupdale N; Cacodcar JA; Kamat U
    Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.